Engineered Bacterial Outer Membrane Vesicles for Tumor Diagnosis and Treatment: A Review
Source abstract
Abstract
Abstract Bacterial outer membrane vesicles (OMVs) are spherical bilayer nanostructures that typically range from 20 to 250 nm in diameter and are secreted by Gram-negative bacteria as part of their normal growth process. These vesicles contain multiple pathogen-associated molecular patterns (PAMPs) derived from the bacterial outer membrane and periplasm, which stimulate the expression of cytokines and costimulatory molecules in immune cells, thereby promoting antigen presentation and activating systemic immunity. Moreover, OMVs can be modified by different approaches, endowing them with great potential for applications in disease treatment and diagnosis, such as imaging, antimicrobial treatment, tumor therapy, and so on. This review provides a comprehensive overview of the structural composition, biogenesis mechanisms, and genetic modification methods of OMVs. It then introduces the typical applications of engineered OMVs, such as drug delivery vehicles, adjuvants, tumor vaccines, and tracer materials. Finally, it discusses the future development and potential of OMVs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Microbial Fuel Cells and Bioremediation · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing Institute of Technology , , ,
Peking University , , ,
Ningbo Institute of Marine Medicine , ,
Funding
National Natural Science Foundation of China · China Postdoctoral Science Foundation · National Science Fund for Distinguished Young Scholars
References (100+)
Show source-provided references
1. Outer Membrane Vesicles: Biogenesis, Functions, and Issues10.1128/mmbr.00032-22 ↗
2. Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane10.1096/fj.11-188425 ↗
3. Peptidoglycan recognition by Pal, an outer membrane lipoprotein10.1021/bi052227i ↗
4. Types and origins of bacterial membrane vesicles10.1038/s41579-018-0112-2 ↗
5. Role of Pseudomonas aeruginosa peptidoglycan-associated outer membrane proteins in vesicle formation10.1128/JB.01253-12 ↗
6. Outer membrane vesicles in gram-negative bacteria and its correlation with pathogenesis10.3389/fimmu.2025.1541636 ↗
7. Bioengineering modification and application of bacterial outer membrane vesicles10.7150/ijms.116432 ↗
8. Outer membrane vesicles: A bacterial-derived vaccination system10.3389/fmicb.2022.1029146 ↗
9. An extracellular glycolipid produced by Escherichia coli grown under lysine-limiting conditions10.1042/bj0960567 ↗
10. Outer Membrane Vesicle Induction and Isolation for Vaccine Development10.3389/fmicb.2021.629090 ↗
11. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery10.1016/j.addr.2017.05.003 ↗
12. Bacterial outer membrane vesicles as a candidate tumor vaccine platform10.3389/fimmu.2022.987419 ↗
13. Biogenesis of bacterial membrane vesicles10.1111/j.1365-2958.2009.06731.x ↗
14. Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy10.1016/j.addr.2022.114321 ↗
15. Outer Membrane Vesicle Biosynthesis in Salmonella: Is There More to Gram-Negative Bacteria?10.1128/mBio.01282-16 ↗
16. Smart molecular design for functional cellulose gels and flexible devices10.1002/smo2.70038 ↗
17. Bacterial Outer Membrane Vesicles as a Versatile Tool in Vaccine Research and the Fight against Antimicrobial Resistance10.1128/mBio.01707-21 ↗
18. Protein selection and export via outer membrane vesicles10.1016/j.bbamcr.2013.12.011 ↗
19. Bacterial outer membrane vesicles as a platform for biomedical applications: An update10.1016/j.jconrel.2020.04.031 ↗
20. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions10.1038/nrmicro3525 ↗
21. Bacterial outer membrane vesicle-based cancer nanovaccines10.20892/j.issn.2095-3941.2022.0452 ↗
22. Bacterial outer membrane vesicles in cancer: Biogenesis, pathogenesis, and clinical application10.1016/j.biopha.2023.115120 ↗
23. Modulation of bacterial outer membrane vesicle production by envelope structure and content10.1186/s12866-014-0324-1 ↗
24. Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy10.1016/j.actbio.2021.12.005 ↗
25. Dysregulated hemolysin liberates bacterial outer membrane vesicles for cytosolic lipopolysaccharide sensing10.1371/journal.ppat.1007240 ↗
26. Engineering Versatile Bacteria-Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy10.1002/advs.202400049 ↗
27. Helicobacter pylori Outer Membrane Vesicles: Biogenesis, Composition, and Biological Functions10.7150/ijbs.94156 ↗
28. Bacterial outer membrane vesicles and host cell death signaling10.1016/j.tim.2021.04.003 ↗
29. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms10.1007/978-3-662-43492-5_1 ↗
30. Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo10.1371/journal.pone.0002461 ↗
31. Outer membrane vesicles as next-generation vaccine platforms: Mechanisms of antigen presentation10.1016/j.intimp.2025.116075 ↗
32. Outer Membrane Vesicles (OMVs) of Gram-negative Bacteria: A Perspective Update10.3389/fmicb.2017.01053 ↗
33. OMV Vaccines and the Role of TLR Agonists in Immune Response10.3390/ijms21124416 ↗
34. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B10.1128/IAI.00846-07 ↗
35. Immune modulation by bacterial outer membrane vesicles10.1038/nri3837 ↗
36. Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies10.5306/wjco.v17.i2.114423 ↗
37. A novel role for the bactericidal/permeability increasing protein in interactions of gram-negative bacterial outer membrane blebs with dendritic cells10.4049/jimmunol.179.4.2477 ↗
38. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo10.4049/jimmunol.179.11.7692 ↗
39. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy10.1017/erm.2022.8 ↗
40. Histophilus somni causes extracellular trap formation by bovine neutrophils and macrophages10.1016/j.micpath.2012.09.007 ↗
41. The membrane expression of Neisseria meningitidis adhesin A (NadA) increases the proimmune effects of MenB OMVs on human macrophages, compared with NadA- OMVs, without further stimulating their proinflammatory activity on circulating monocytes10.1189/jlb.0109030 ↗
42. NO production in RAW264 cells stimulated with Porphyromonas gingivalis extracellular vesicles10.1111/j.1601-0825.2010.01708.x ↗
43. Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity10.1158/2767-9764.CRC-25-0509 ↗
44. Gene expression and production of tumor necrosis factor alpha, interleukin-1beta (IL-1beta), IL-8, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles10.1128/IAI.68.12.6917-6923.2000 ↗
45. Spatiotemporal controls of neutrophil extracellular traps boosts neutrophils immunotherapy efficiency against solid tumors10.1016/j.biomaterials.2026.124012 ↗
46. Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis10.1128/IAI.00637-06 ↗
47. Bacteria-based immunosuppressive tumor microenvironment reprogramming: a promising dawn in cancer therapy10.1186/s12934-025-02838-2 ↗
48. Engineered bacteria and bacteria-derived nanomaterials for cancer therapy: Mechanisms, designs and advances10.1016/j.bioactmat.2025.09.012 ↗
49. Engineering Bacteria and Their Derivatives for Cancer Immunotherapy10.34133/bmef.0047 ↗
50. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery10.1038/s41596-022-00713-7 ↗
51. Multifaceted therapeutic applications of biomimetic nanovaccines10.1016/j.drudis.2024.103991 ↗
52. Phytochemical Engineered Bacterial Outer Membrane Vesicles for Photodynamic Effects Promoted Immunotherapy10.1021/acs.nanolett.2c01280 ↗
53. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology10.1038/s41467-021-22308-8 ↗
54. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy10.1021/nn405724x ↗
55. Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy10.1002/adma.202002085 ↗
56. Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ Vaccine for Cancer Immunotherapy Post-Photothermal Therapy10.1002/smll.202107461 ↗
57. Harnessing Hitchhikers: Outer Membrane Vesicles Leading the Way in Advanced Cancer Therapeutics and Diagnostic- A Review10.1016/j.canlet.2026.218370 ↗
58. Engineered Bacterial Outer Membrane Vesicles as Controllable Two-Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy10.1002/adma.202206200 ↗
59. Engineering bacterial outer membrane vesicles synergetically boost superactivated anti-tumor immunity induced by radiotherapy via sustained DNA damage10.1016/j.bioadv.2026.214780 ↗
60. Bacterial extracellular vesicles: an emerging avenue to tackle diseases10.1016/j.tim.2023.05.010 ↗
61. Bioengineering bacterial outer membrane vesicles as vaccine platform10.1016/j.biotechadv.2017.05.003 ↗
62. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines10.1186/s12934-014-0162-8 ↗
63. Heme binding proteins of Bartonella henselae are required when undergoing oxidative stress during cell and flea invasion10.1371/journal.pone.0048408 ↗
64. Positional assembly of enzymes on bacterial outer membrane vesicles for cascade reactions10.1371/journal.pone.0097103 ↗
65. Selective Identification of Allosteric Inhibitors and Co-Drug Combinations Targeting Kinases by Using a Nanopore Tweezer Approach10.1021/acsnano.5c07468 ↗
66. Outer membrane vesicles from Escherichia coli as a presentation platform for AR-23 antiviral peptide10.3389/fmolb.2025.1607578 ↗
67. Inhalable Nanovaccine Based on Bioengineered Bacteria-Derived Membrane Vesicles Against Lung Metastasis10.1002/adma.202506174 ↗
68. Salmonella typhimurium co-expressing cytolysin A and hyaluronidase suppresses tumor growth and metastasis10.1038/s41420-025-02897-9 ↗
69. Engineered Bacteria-Vesicle Delivered Lactate Reprogramming Boosts Tumor Radiosensitivity10.1002/advs.202524303 ↗
70. Engineered Low-Endotoxin Bacterial Biomimetic Vesicles for Enhanced Oral Dual-Antigen Subunit Vaccine Delivery10.1002/jev2.70207 ↗
71. Engineered Escherichia coli Nissle 1917 targeted delivery of extracellular PD-L1-mFc fragment for treating inflammatory bowel disease10.1016/j.apsb.2025.08.002 ↗
72. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA10.1128/IAI.72.12.7096-7106.2004 ↗
73. Recent advances in chemiluminescence probes for Tumor microenvironment with applications in cancer diagnosis and therapy10.1016/j.pscia.2026.100113 ↗
74. Multiplexed biosensing: A review of surface plasmon resonance platforms for biomarker analysis10.1016/j.talanta.2026.129564 ↗
75. Advances in the designing endoplasmic reticulum-targeted fluorescent probes10.1016/j.bioorg.2026.109619 ↗
76. Roadmap for light interaction with biophotonic surfaces and their diverse applications10.1117/1.JBO.31.6.064302 ↗
77. From spectroscopic analysis to clinical imaging: emerging applications and persistent challenges of raman spectroscopy in CTCs-based liquid biopsies10.1080/07853890.2026.2634462 ↗
78. Targeting Pyroptosis through Lipopolysaccharide-Triggered Noncanonical Pathway for Safe and Efficient Cancer Immunotherapy10.1021/acs.nanolett.3c02728 ↗
79. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response10.1038/s41467-017-00729-8 ↗
80. Versatility of bacterial outer membrane vesicles in regulating intestinal homeostasis10.1126/sciadv.ade5079 ↗
81. Visualizing transfer of microbial biomolecules by outer membrane vesicles in microbe-host-communication in vivo10.1002/jev2.12159 ↗
82. Applications of magnetic nanoparticles for nucleic acid extraction and analysis in biological and biomedical fields10.1016/j.talanta.2025.129238 ↗
83. Micro-/nanorobots in nanomedicine - Guidance, imaging and the integration of AI and robotics10.1016/j.bbrc.2026.153390 ↗
84. Antibody-based nanoparticles in Alzheimer’s disease: Innovations in diagnosis and therapy10.1016/j.prp.2026.156421 ↗
85. Ultrasound-Mediated Nanocarrier-Based Drug Delivery in Breast Cancer Therapy: Innovations and Outlook10.1002/jum.70117 ↗
86. Bioinspired and stimuli-responsive nanocomposites for targeted therapy in ovarian and endometrial tumors10.1016/j.ijpx.2026.100493 ↗
87. Magnetically Powered Immunogenic Macrophage Microrobots for Targeted Multimodal Cancer Therapy10.1002/smll.202301489 ↗
88. Gene editing tool-loaded biomimetic cationic vesicles with highly efficient bacterial internalization for in vivo eradication of pathogens10.1186/s12951-024-03065-4 ↗
89. Plasmonic Nanotheranostics: Merging Imaging and Therapy on a Unified Platform for Precision Oncology10.1021/acsabm.5c02583 ↗
90. Nanoengineering of Porphyrin-Based Biomaterials for Innovative Cancer Therapy10.1002/tcr.202500306 ↗
91. Recent advances in inorganic nanocomposites for the photothermal therapy of bone tumors10.1039/D5NH00692A ↗
92. Metal nanoparticle-mediated photothermal therapy for bacterial eradication: Mechanisms, strategies, and clinical challenges10.1016/j.colsurfb.2026.115593 ↗
93. Bioengineered Bacterial Membrane Vesicles with Multifunctional Nanoparticles as a Versatile Platform for Cancer Immunotherapy10.1021/acsami.2c18244 ↗
94. Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy10.1038/s41467-020-14963-0 ↗
95. Bacterial outer membrane vesicle-templated biomimetic nanoparticles for synergistic photothermo-immunotherapy10.1016/j.nantod.2022.101591 ↗
96. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging10.1038/s41467-019-09034-y ↗
97. Self-Assembling Endogenous Biliverdin as a Versatile Near-Infrared Photothermal Nanoagent for Cancer Theranostics10.1002/adma.201900822 ↗
98. Outer Membrane Vesicles Derived From Fusobacterium nucleatum Trigger Periodontitis Through Host Overimmunity10.1002/advs.202400882 ↗
99. Field cancerization in breast cancer10.1002/path.5902 ↗
100. Measuring cancer evolution from the genome10.1002/path.4821 ↗